全文获取类型
收费全文 | 324篇 |
免费 | 14篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 26篇 |
口腔科学 | 1篇 |
临床医学 | 36篇 |
内科学 | 124篇 |
神经病学 | 67篇 |
特种医学 | 1篇 |
外科学 | 12篇 |
综合类 | 3篇 |
预防医学 | 11篇 |
眼科学 | 19篇 |
药学 | 18篇 |
肿瘤学 | 15篇 |
出版年
2024年 | 2篇 |
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 12篇 |
2020年 | 8篇 |
2019年 | 14篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 5篇 |
2015年 | 15篇 |
2014年 | 14篇 |
2013年 | 21篇 |
2012年 | 16篇 |
2011年 | 19篇 |
2010年 | 15篇 |
2009年 | 9篇 |
2008年 | 18篇 |
2007年 | 29篇 |
2006年 | 23篇 |
2005年 | 22篇 |
2004年 | 23篇 |
2003年 | 8篇 |
2002年 | 10篇 |
2001年 | 10篇 |
2000年 | 6篇 |
1999年 | 1篇 |
1998年 | 5篇 |
1997年 | 4篇 |
1996年 | 6篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有338条查询结果,搜索用时 392 毫秒
51.
52.
Hitomi Sumiyoshi Okuma Hiroshi Yoshida Yoshihisa Kobayashi Motoko Arakaki Chiharu Mizoguchi Lina Inagaki Pei Jye Voon Adam Malik Bin Ismail Hwoei Fen Soo Hoo Suhana Yusak Marcelo Severino B. Imasa Thinh Nguyen Huy Tu Thai Anh Shinji Kohsaka Hiroyuki Mano Kan Yonemori Kenichi Nakamura Yasushi Yatabe 《Cancer science》2023,114(6):2664-2673
Tissue specimen quality assurance is a major issue of precision medicine for rare cancers. However, the laboratory standards and quality of pathological specimens prepared in Asian hospitals remain unknown. To understand the methods in Southeast Asian oncology hospitals and to clarify how pre-analytics affect the quality of formalin-fixed paraffin-embedded (FFPE) specimens, a questionnaire surveying pre-analytical procedures (Part I) was administered, quality assessment of immunohistochemistry (IHC) staining and DNA/RNA extracted from the representative FFPE specimens from each hospital (Part II) was conducted, and the quality of DNA/RNA extracted from FFPE of rare-cancer patients for genomic sequencing (Part III) was examined. Quality measurements for DNA/RNA included ΔΔCt, DV200, and cDNA yield. Six major cancer hospitals from Malaysia, Philippines, and Vietnam participated. One hospital showed unacceptable quality for the DNA/RNA assessment, but improved by revising laboratory procedures. Only 57% (n = 73) of the 128 rare-cancer patients' specimens met both DNA and RNA quality criteria for next-generation sequencing. Median DV200 was 80.7% and 64.3% for qualified and failed RNA, respectively. Median ΔΔCt was 1.25 for qualified and 4.89 for failed DNA. Longer storage period was significantly associated with poor DNA (fail to qualify ratio = 1579:321 days, p < 0.001) and RNA (fail to qualify ratio = 1070:280 days, p < 0.001). After improvement of pre-analytical factors, the qualification rate increased for hospitals A and E from 41.5% to 70.5% and 62.5% to 86%, respectively. This is the first report to elucidate the pre-analytical laboratory procedures of main Southeast Asian oncology hospitals. An external quality assessment program may improve factors associated with tumor FFPE specimen quality. 相似文献
53.
54.
Cheng KH Chu CS Lee KT Lin TH Voon WC Tsai LY Sheu SH Lai WT 《International journal of cardiology》2008,128(1):126-128
We described a massive non compaction cardiomyopathy associated with Antiphospholipid syndrome in a 53-year-old male with many episodes of ischemic cerebral stroke complicated by functional disability, cognitive decline and vascular dementia. In our case, the association of massive non compaction cardiomyopathy and severe left ventricular dysfunction added to Antiphospholipid syndrome has showed a dramatic thromboembolic manifestation. 相似文献
55.
Yasuto Takeuchi Natsuko Kimura Takahiko Murayama Yukino Machida Daisuke Iejima Tatsunori Nishimura Minoru Terashima Yuming Wang Mengjiao Li Reiko Sakamoto Mizuki Yamamoto Naoki Itano Yusuke Inoue Masataka Ito Nobuaki Yoshida Jun-ichiro Inoue Koichi Akashi Hideyuki Saya Koji Fujita Masahiko Kuroda Issay Kitabayashi Dominic Voon Takeshi Suzuki Arinobu Tojo Noriko Gotoh 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(43)
56.
Laurel S Morris Kwangyeol Baek Prantik Kundu Neil A Harrison Michael J Frank Valerie Voon 《Neuropsychopharmacology》2016,41(4):940-948
We focus on exploratory decisions across disorders of compulsivity, a potential dimensional construct for the classification of mental disorders. Behaviors associated with the pathological use of alcohol or food, in alcohol use disorders (AUD) or binge-eating disorder (BED), suggest a disturbance in explore–exploit decision-making, whereby strategic exploratory decisions in an attempt to improve long-term outcomes may diminish in favor of more repetitive or exploitatory choices. We compare exploration vs exploitation across disorders of natural (obesity with and without BED) and drug rewards (AUD). We separately acquired resting state functional MRI data using a novel multi-echo planar imaging sequence and independent components analysis from healthy individuals to assess the neural correlates underlying exploration. Participants with AUD showed reduced exploratory behavior across gain and loss environments, leading to lower-yielding exploitatory choices. Obese subjects with and without BED did not differ from healthy volunteers but when compared with each other or to AUD subjects, BED had enhanced exploratory behaviors particularly in the loss domain. All subject groups had decreased exploration or greater uncertainty avoidance to losses compared with rewards. More exploratory decisions in the context of reward were associated with frontal polar and ventral striatal connectivity. For losses, exploration was associated with frontal polar and precuneus connectivity. We further implicate the relevance and dimensionality of constructs of compulsivity across disorders of both natural and drug rewards. 相似文献
57.
58.
Byoung Chul Cho Busayamas Chewaskulyong Ki Hyeong Lee Arunee Dechaphunkul Virote Sriuranpong Fumio Imamura Naoyuki Nogami Takayasu Kurata Isamu Okamoto Caicun Zhou Ying Cheng Eun Kyung Cho Pei Jye Voon Jong-Seok Lee Helen Mann Matilde Saggese Thanyanan Reungwetwattana Suresh S. Ramalingam Yuichiro Ohe 《Journal of thoracic oncology》2019,14(1):99-106
Introduction
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI–sensitizing mutations.Methods
Eligible Asian patients (enrolled at Asian sites) who were at least 18 years of age (≥20 years in Japan) and had untreated EGFR-mutated advanced NSCLC were randomized 1:1 to receive osimertinib (80 mg, orally once daily) or an SoC EGFR TKI (gefitinib, 250 mg, or erlotinib, 150 mg, orally once daily). The primary end point was investigator-assessed progression-free survival (PFS). The key secondary end points were overall survival, objective response rate, central nervous system efficacy, and safety.Results
The median PFS was 16.5 versus 11.0 months for the osimertinib and SoC EGFR TKI groups, respectively (hazard ratio = 0.54, 95% confidence interval: 0.41–0.72, p < 0.0001). The overall survival data were immature (24% maturity). The objective response rates were 80% for osimertinib and 75% for an SoC EGFR TKI. The median central nervous system PFS was not calculable for the osimertinib group and was 13.8 months for the SoC EGFR TKI group (hazard ratio = 0.55, 95% confidence interval: 0.25–1.17, p = 0.118). Fewer adverse events of grade 3 or higher (40% versus 48%) and fewer adverse events leading to treatment discontinuation (15% versus 21%) were reported with osimertinib versus with an SoC EGFR TKI, respectively.Conclusion
In this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population. 相似文献59.
C.N. Chua MRCP FRCOphth F. Quhill MBChB BmedSc E. Jones MRCOphth L.W. Voon FRCS M. Ahad FRCS N. Rowson FRCS FRCOphth 《Orbit (Amsterdam, Netherlands)》2013,32(4):213-218
purpose To assess the effect and efficacy of botulinum toxin type A (BTX-A) at reducing and maintaining eyelid synkinesia in aberrant facial nerve regeneration, while concurrently observing for the presence of side effects to differing treatment doses. methods A prospective interventional study of five patients with eyelid synkinesia resulting from aberrant regeneration of the facial nerve. Patients were treated with injections of either 120, 80 or 40 units of BTX-A (Dysport) into the orbicularis oculi. Objective and subjective reduction in synkinesia, maintenance of response and presence of side effects were recorded. results All five patients had improvement of the synkinesia with BTX-A treatment. Lower doses were found to be as effective as higher doses. Mean duration of abolished synkinesia was three months. Two patients developed a ptosis which resolved spontaneously. None of the patients treated with the lowest dose of 40 units developed a ptosis. conclusion Low-dose BTX-A has a lower incidence of ptosis and is effective in the treatment of aberrant facial nerve regeneration. 相似文献
60.
Multi‐omics analysis identifies pathways and genes involved in diffuse‐type gastric carcinogenesis induced by E‐cadherin,p53, and Smad4 loss in mice 下载免费PDF全文